Gilead: Near-Term Drug Filings Planned, But HIV Pressure Persists
This article was originally published in The Pink Sheet Daily
Executive Summary
Gilead expects to file for a new triple combination, Truvada plus Johnson & Johnson's TMC278, later this year, to extend the life of its HIV franchise.
You may also be interested in...
Gilead's Quad Poised To Take Chunk Of Atripla's Market, If Phase III Results Hold Up
Solid efficacy with fewer psych effects than Atripla continue in full-length version of Phase II trials. However, hopes for superior performance have started to wane.
Gilead's Quad Poised To Take Chunk Of Atripla's Market, If Phase III Results Hold Up
Solid efficacy with fewer psych effects than Atripla continue in full-length version of Phase II trials. However, hopes for superior performance have started to wane.
Tibotec Files NNRTI Rilpivirine, Part Of Gilead's New Combo For HIV
Johnson & Johnson subsidiary Tibotec has submitted its once-daily non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine) for treatment-naïve HIV patients for FDA approval, close on the heels of releasing pivotal data at the International AIDS Society meeting in Vienna